DIAGNOSIS AND TREATMENT OF MF AND PV: Where Are We and Where Are We Going?

Target Audience
This educational program is directed toward medical oncologists, hematologists, and other health care professionals who treat patients with MPNs. Fellows, researchers, nurse practitioners, nurses, physician assistants, and other allied professionals interested in hematologic malignancies are also invited to attend.

Activity Overview
Myeloproliferative neoplasms (MPNs) comprise a diverse range of hematologic cancers, with optimal management requiring careful risk stratification and treatment planning. In recent years, refinements in disease biology and development of novel therapeutic options have led to improved control of symptoms and lessened risk of serious adverse events.

This virtual, on-demand webcast is specifically designed to meet the needs of busy clinicians who treat patients who have received a diagnosis of polycythemia vera (PV) or myelofibrosis (MF) by providing an update on optimal diagnosis, treatment selection, and emerging therapeutic options. These didactic presentations are placed into real-world context through discussion of 5 case scenarios spanning the disease continuum for PV and MF. These cases will help place recent findings and treatment recommendations into context for participants.

This educational activity is an archive of the virtual symposium held on December 10, 2021.

Learning Objectives
Upon completion of this activity, you should be better able to:

Determine the impact of genetics, symptom burden, and risk stratification on therapy selection in MPNs
Evaluate the clinical profiles of current and emerging therapeutic strategies in MPNs across lines of therapy
Identify and manage disease-associated symptoms and treatment-related toxicities in patients with MPNs
Translate updated clinical trial evidence and guidelines into personalized treatment plans for patients with MPNs to optimize care across the disease continuum